These are top 10 stocks traded on the Robinhood UK platform in July
Investing.com - H.C. Wainwright raised its price target on atai Life Sciences N.V (NASDAQ:ATAI) to $15.00 from $10.00 on Thursday, while maintaining a Buy rating on the stock. Currently trading at $3.47, the biotech company has a market capitalization of $736 million. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $7 to $15.
The price target increase follows atai’s July 25 announcement that its Phase 2b trial for inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia missed its primary endpoint.
H.C. Wainwright noted that management plans to focus resources on atai’s wholly-owned psychedelics pipeline, particularly BPL-003, which has demonstrated robust efficacy and a favorable safety profile in treating depression.
The firm highlighted BPL-003’s compelling top-line Phase 2b data in treatment-resistant depression, which showed statistically significant reductions in the MADRS depression scale as early as Day 2, with most patients becoming discharge-ready within 90 minutes.
Based on these results, H.C. Wainwright increased its probability of success for BPL-003 to 85% from 60% previously, while removing RL-007 from its valuation model as atai prepares to engage regulators in the third quarter of 2025 and initiate a Phase 3 trial in the first half of 2026.
In other recent news, atai Life Sciences has been in the spotlight following several significant developments. The company announced that its Phase 2b clinical trial for inidascamine, a treatment for cognitive impairment associated with schizophrenia, did not meet its primary endpoint. Despite this setback, the drug showed modest improvements across multiple cognitive domains and maintained a favorable safety profile. On a more positive note, atai’s BPL-003 treatment for treatment-resistant depression delivered successful Phase 2b trial results, meeting both primary and key secondary endpoints. This led Canaccord Genuity to raise its price target for atai Life Sciences to $12, maintaining a Buy rating. Similarly, Aegis Capital reiterated its Buy rating with an $8 price target following these promising results. H.C. Wainwright also maintained its Buy rating and a $10 price target, emphasizing the statistically significant improvements observed in the trial. Additionally, Oppenheimer initiated coverage of atai Life Sciences with an Outperform rating and a $14 price target, highlighting the company’s potential in the neuropsychiatry sector. These developments reflect a mix of challenges and opportunities for atai Life Sciences as it navigates its clinical trials and market evaluations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.